ImmuniT Platform for Improved Neoantigen Prediction in Lung Cancer.

ABSTRACT:

Background

Lung cancer remains the leading cause of cancer-related mortality, with many patients responding poorly to immunotherapy due to limited tumor recognition. Neoantigen-based strategies offer a promising solution, but current discovery methods often miss key targets, particularly those with low or heterogeneous expression. To address this, we developed ImmuniT, a three-phase platform for enhanced neoantigen discovery and validation.

Methods

Under an IRB-approved protocol, patients with lung cancer consented to tumor collection for ex vivo processing to modulate antigen expression. Autologous T cells from matched blood were co-cultured with treated cancer cells to expand tumor-reactive populations. The nextneopi pipeline integrated mutational, transcriptomic, and HLA

SUBMITTER: Hachey SJ 

PROVIDER: S-EPMC12474151 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature